Drug-Drug Interaction Study of "CG-651" in Healthy Volunteer
NCT ID: NCT05370716
Last Updated: 2022-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
47 participants
INTERVENTIONAL
2019-11-11
2020-05-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers
NCT04237597
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501
NCT03089112
Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers
NCT03366974
Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816
NCT02554136
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
NCT05723510
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\[Group A\] Pregabalin+ Polmacoxib. \[Group B\] Polmacoxib \[Group C\] Pregabalin
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Group B: Polmacoxib
* Group C: Pregabalin
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Pregabalin + Polmacoxib
Polmacoxib
Polmacoxib
Pregabalin
Pregabalin
Group B
Polmacoxib
Polmacoxib
Polmacoxib
Group C
Pregabalin
Pregabalin
Pregabalin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polmacoxib
Polmacoxib
Pregabalin
Pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject who understand the objective, method of the study and the characteristics of investigational drug and expected adverse events and provide written informed consent prior to study participation.
* Negative pregnancy test (hCG) and agree to contraception during the trial.
Exclusion Criteria
* History of hypersensitivity or allergic reaction to sulfonamide.
* Patients with a history of asthma, acute rhinitis, non specific polyps, angioedema, urticaria or allergic reactions to aspirin or other nonsteroidal anti-inflammatory analgesics(including COX-2 inhibitors)
* Any other reason or situations that the investigator decides the patient is not eligible to participate the clinical trial.
19 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CrystalGenomics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CG100651-1-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.